Publikationen: Beitrag in Fachzeitschrift › Zeitschriftenaufsätze › Forschung
A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. / Schiedner, Gudrun; Bloch, Wilhelm; Hertel, Sabine; Johnston, Marion; Molojavyi, Andrei; Dries, Volker; Varga, Georg; Van Rooijen, Nico; Kochanek, Stefan.
in: Human gene therapy, Jahrgang 14, Nr. 17, 20.11.2003, S. 1631-1641.Publikationen: Beitrag in Fachzeitschrift › Zeitschriftenaufsätze › Forschung
}
TY - JOUR
T1 - A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells
AU - Schiedner, Gudrun
AU - Bloch, Wilhelm
AU - Hertel, Sabine
AU - Johnston, Marion
AU - Molojavyi, Andrei
AU - Dries, Volker
AU - Varga, Georg
AU - Van Rooijen, Nico
AU - Kochanek, Stefan
PY - 2003/11/20
Y1 - 2003/11/20
N2 - Intravascular injection of adenoviral vectors may result in a toxic and potentially lethal reaction, the mechanism of which is poorly understood. We noted that mice demonstrated a transient change in behavior that was characterized by inactivity and lethargy within minutes after intravenous injection of relatively low doses of adenoviral vectors (including high-capacity gutless vectors). Moreover, immediately after vector injection a significant drop in blood pressure was measured that most probably was caused by the systemic activation of endothelial cells as monitored by detection of phosphorylated Akt/PKB kinase, activated endothelial nitric oxide synthase (eNOS), and nitrotyrosine. The activation of the endothelium was the result of the interaction of viral particles with Kupffer cells, which are resident macrophages of the liver representing the first line of defense of the innate immune system. Surprisingly, the uptake of vector particles by Kupffer cells not only resulted in their strong activation, but also in their nearly complete disappearance from the liver. Our results suggest that the toxicity of intravenously injected adenoviral vectors may be directly linked to the activation and destruction of Kupffer cells.
AB - Intravascular injection of adenoviral vectors may result in a toxic and potentially lethal reaction, the mechanism of which is poorly understood. We noted that mice demonstrated a transient change in behavior that was characterized by inactivity and lethargy within minutes after intravenous injection of relatively low doses of adenoviral vectors (including high-capacity gutless vectors). Moreover, immediately after vector injection a significant drop in blood pressure was measured that most probably was caused by the systemic activation of endothelial cells as monitored by detection of phosphorylated Akt/PKB kinase, activated endothelial nitric oxide synthase (eNOS), and nitrotyrosine. The activation of the endothelium was the result of the interaction of viral particles with Kupffer cells, which are resident macrophages of the liver representing the first line of defense of the innate immune system. Surprisingly, the uptake of vector particles by Kupffer cells not only resulted in their strong activation, but also in their nearly complete disappearance from the liver. Our results suggest that the toxicity of intravenously injected adenoviral vectors may be directly linked to the activation and destruction of Kupffer cells.
KW - Adenoviridae
KW - Animals
KW - Blood Pressure
KW - Eicosanoids
KW - Endothelial Cells
KW - Endothelium
KW - Endothelium, Vascular
KW - Enzyme Activation
KW - Gene Transfer Techniques
KW - Genetic Therapy
KW - Genetic Vectors
KW - Immunohistochemistry
KW - Injections, Intravenous
KW - Kupffer Cells
KW - Liver
KW - Macrophages
KW - Mice
KW - Mice, Inbred C57BL
KW - Microscopy, Electron
KW - Nitric Oxide Synthase
KW - Nitric Oxide Synthase Type II
KW - Nitric Oxide Synthase Type III
KW - Phosphorylation
KW - Radioimmunoassay
KW - Spleen
KW - Time Factors
KW - Tyrosine
U2 - 10.1089/104303403322542275
DO - 10.1089/104303403322542275
M3 - Journal articles
C2 - 14633405
VL - 14
SP - 1631
EP - 1641
JO - Human gene therapy
JF - Human gene therapy
SN - 1043-0342
IS - 17
ER -
ID: 72215